3 Cheap Dividend Stocks I'd Buy Without Any Hesitation

The article presents Bristol Myers Squibb, Target and PepsiCo as inexpensive dividend-stock opportunities, citing forward yields of 4.2%, 3% and 4.3%, respectively. Bristol Myers Squibb has raised its annual dividend for 17 consecutive years; Target’s same-store sales rose 3.8% in the quarter ending in early August, while PepsiCo reported 3.1% third-quarter organic revenue growth. The author notes ongoing risks, including Target’s uncertain turnaround and PepsiCo’s exposure to inflation through its production facilities.

Analysis

The common risk is treating a low earnings multiple and a high yield as downside protection. Those metrics offer little defense if earnings estimates or dividend coverage deteriorate. The article’s operating signals are preliminary, not proof of durable recovery.

Near term, the main distinction is earnings quality: BMY is an income-and-patent-cycle exposure; TGT is a discretionary-demand and execution turnaround; PEP is exposed to owned-manufacturing costs as well as consumer demand. PEP’s revenue acceleration matters only if it reaches operating margins and cash flow. KO’s asset-light bottling model is a useful operating-structure comparison, but the supplied facts do not establish a valuation-based pair trade.

Over 1–3 months, monitor TGT comparable sales alongside margins, inventory/promotions and guidance; a sales rebound driven by discounting would weaken the turnaround case. For PEP, verify whether organic growth translates to margins and free cash flow rather than assuming inflation pressure has passed. Over 6–18 months, BMY’s key risk is whether products and pipeline can offset any material loss of exclusivity; verify product-level revenue exposure and cash-flow coverage before underwriting the dividend. The article provides no payout-coverage, patent-timing or valuation-history data.

Contrarian read: “little downside left” and “without a second thought” are not supported by the cited multiples alone. A yield can reflect expected earnings erosion, while a CEO change does not establish a retail inflection. No immediate broad buy signal; prefer staged exposure with operating confirmation.

Key Decisions for Investors

• BMY: Consider only a modest, income-oriented position after checking product-level patent/exclusivity timelines, pipeline contribution and free-cash-flow dividend coverage. Reassess if guidance or cash flow indicates weaker coverage; the yield and low multiple alone are not a catalyst.
• TGT: Keep on a catalyst watchlist rather than buying the comp rebound outright. Add only if subsequent results show sales improvement alongside stable/improving gross margins and inventory discipline. Falsifier: comps supported by heavier promotions, or guidance/margins weakening.
• PEP: Stagger any long entry and require evidence that organic growth is converting into operating margin and cash flow. If revenue growth accelerates but margins continue to contract, avoid or reduce exposure; monitor input costs and promotional intensity.
• No KO/PEP pair or options trade yet: comparable valuation, margin and earnings-revision data are missing. Revisit relative positioning when those measures and the next earnings updates are available.